

Australasian Leukaemia and Lymphoma Group Tissue Bank (ALLG Tissue Bank)

Total Holdings as of 11th October 2011

(49,969 samples available from 1975 consented patients with confirmed haematologic malignant disease)

Please note for the following slides:

- The sample numbers detailed under each WHO classification are made up of both diagnostic (Dx) and follow up (F/U) collections. Thus serial samples sets are available.
- The samples numbers listed under each classification are against total patient numbers - this does not imply that every patient has every sample type listed.
- The sample types listed have been processed from bone marrow aspirate (BM) and/or peripheral blood (PB) specimens. For most patients, BM and PB specimens are collected at each subsequent collection date.
- For further detail on specific holdings or for a more comprehensive breakdown of specimen /sample types available for your research project please contact the Tissue Bank Manager directly.

Megan Ellis – ALLG Tissue Bank Manager
Princess Alexandra Hospital - QLD

Ph: (07) 3176 5835 or

megan_ellis@health.qld.gov.au

Tissue Bank Holdings by Diagnosis to 11th Oct 2011

– please see further graphs for breakdown

WHO - Major classification	Tissue Bank CODE	No. of samples per	No. of patients per
Acute Myeloid Leukaemia	AML	21,150	546
Mature B-cell Neoplasms	B NEO	15,496	798
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1	MALN	82	1
Mastocytosis	MAST	20	1
Myeloproliferative neoplasms	MPN	1110	32
Precursor lymphoid neoplasms	PLN	531	12
Chronic Myeloproliferative Diseases	CMPD	5285	199
Mature T-cell and NK-cell neoplasms	T/NK	1773	46
Myelodysplastic syndromes	MDS	2083	147
Hodgkin Lymphoma	HD	588	120
Myelodysplastic/Myeloproliferative Diseases	MDS/MPD	1466	49
Miscellaneous	MISC	244	19
Immunodeficiency associated lymphoproliferative disorders	IDALPD	141	5
Histiocytic and dendritic cell neoplasms	HIST	0	0
TOTAL		49,969	1,975

AML 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are from BM, PB or both per patient

AML 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
AML with trilineage dysplasia	AML/TLD	59	2	8	35	1	27	132	6
AML with abnormal BM eosinophils	AML16	48	0	11	7	1	20	87	4
AML with t(8;21)	AML821	126	6	10	27	0	83	252	8
AML with multilineage dysplasia WITH prior myelodysplasia	AMLAMDS	145	4	50	49	10	138	396	16
AML with multilineage dysplasia WITHOUT prior myelodysplasia	AMLDN	165	8	40	62	8	138	421	8
M0	AML10/M0	166	9	48	21	7	116	367	11
M1	AML11/M1	791	40	248	399	17	465	1960	37
M2	AML12/M2	756	39	243	371	15	438	1862	42
M3 or APML	AML13/M3/APML	1106	14	83	422	0	857	2482	31
M4	AML14/M4	373	19	96	147	3	180	818	24
M5	AML15/M5	411	27	155	260	10	196	1059	30
M6	AML16/M6	70	6	3	17	3	80	179	9
M7	AML17/M7	6	3	0	2	0	12	23	2
Biphenotypic Leukamia	BAL	110	7	19	24	2	102	264	7
No Classification has been recorded	NO CLASS	360	24	89	149	2	287	911	34
Acute Panmyelosis with myelofibrosis	APM	4	0	0	2	0	6	12	1
New Who - BPDC	AMLBPDC	32	0	9	19	1	20	81	1
AMLT	AMLT	352	0	68	127	1	180	728	36
New Who - AML with myelodysplastic changes	NWAMLRC	79	2	22	69	0	35	207	7
New Who - AMLT	NWAMLT								
TOTAL		5159	210	1202	2209	81	3380	12241	314

AML 'Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are processed from either BM or PB specimens or both per patient.

These samples are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are available for approved researchers

AML 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Serum	Total Sample Numbers	Total Patient Numbers
APML4 TOTAL	AMPL4	324	3	18	93	0	182	620	11
AML9 TOTAL	AML9	30	0	31	18	0	5	84	5
AML10 TOTAL	AML10	27	6	29	0	0	12	74	4
AML12 TOTAL	AML12	2004	6	675	758	12	1959	5414	174
AML13 TOTAL	AML13	1091	1	180	427	0	821	2520	33
AML14 TOTAL	AML14	38	0	17	49	0	6	110	4
LBH/AZA	LBH/AZA	27	0	28	28	0	4	87	1
GRAND TOTAL ('AML' Trial and Non Trial)		8700	226	2180	3582	93	6369	21150	546

B NEO 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

B NEO 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Tissue	DNA	Serum	Total Sample Numbers	Total Patient Numbers
Precursor B Lymphoblastic Leukaemia/Lymphoma	PB ALL	904	35	218	343	1	0	595	2096	46
Burkitt Lymphoma	BL	41	19	6	14	5	0	23	108	7
B-cell Prolymphocytic Leukaemia	BPLL	34	0	41	46	0	0	8	129	2
Chronic Lymphocytic Leukaemia	CLL	696	8	440	418	0	28	246	1836	66
Chronic Lymphocytic Leukaemia/Prolymphocytic Leukaemia	CLL/PLL	23	0	16	15	1	0	10	65	2
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma	CLL/SLL	315	0	135	243	2	0	118	813	24
Small Lymphocytic Lymphoma	SLL	80	0	2	26	2	0	44	154	10
Chronic Lymphocytic Leukaemia/ Richter's transformation DLBCL	CLL/RTDLB	27	0	0	20	0	0	11	58	1
Diffuse Large B-Cell Lymphoma	DLBCL	314	7	15	188	30	0	155	709	39
Diffuse Large B-Cell Lymphoma - transformed	DCBCLT	0	0	0	0	1	0	0	1	1
T cell/ Histiocyte-rich large B-cell lymphoma	NW-T/HRLBCL	2	0	0	0	1	0	0	3	1
Follicular Lymphoma	FL	473	0	18	231	69	0	279	1070	59
Follicular lymphoma - uninvolved BM	FLUB	4	0	0	0	1	0	5	10	2

B NEO 'Non Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

B NEO 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Tissue	DNA	Serum	Total Sample Numbers	Total Patient Numbers
Low Grade Lymphoma - not otherwise specified	LGLNOS	85	0	3	64	2	0	51	205	11
Hairy Cell Leukaemia	HCL	51	0	1	18	0	0	50	120	8
Lymphoplasmacytic Lymphoma	LPC	306	0	13	85	0	0	211	615	41
Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Tissue	MALT	11	0	0	4	0	0	8	23	1
Mantle Cell Lymphoma	MCL	250	0	48	150	10	0	118	576	23
Mantle Cell Lymphoma - Blastoid variant	MCLBV	21	1	7	6	0	0	21	56	3
Monoclonal Gammopathy of Uncertain Significance	MGUS	468	0	28	236	0	0	239	971	81
Plasma Cell Myeloma	MM	1430	10	77	605	1	0	847	2970	193
Nodal Marginal Zone B-Cell Lymphoma	MZL	107	0	46	48	7	0	35	243	13
EBV Positive diffuse large B-cell lymphoma of the elderly	NW-EBVDLBCL	6	0	0	3	1	0	8	18	1
DLBCL not otherwise specified	NW-DLBCLNOS	10	0	0	13	0	0	11	34	3
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease	NW-HHV8 MCD	9	0	0	1	0	0	7	17	1
Primary amyloidosis - A protein	PA-AA	5	0	0	5	0	0	2	12	1
Primary amyloidosis - Light chain	PA-AL	24	0	0	27	0	0	40	91	10
Primary amyloidosis - Transthyretin	PA-ATTR	2	0	0	1	0	0	0	3	1
Primary amyloidosis - Localised	PA-LOC	1	0	0	3	0	0	2	6	1
Post Transplant Lymphoproliferative disorder polymorphic	PTLDP	9	0	0	4	0	0	5	18	1
Splenic Marginal Zone Lymphoma	SMZL	79	0	3	42	3	0	39	166	6
No classification recorded	?Classification	122	0	6	81	1	0	62	272	16
TOTAL		5909	80	1123	2940	138	28	3250	13468	675

B-CELL NEOPLASM (B NEO) 'Trial' Classification Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are processed from either BM or PB specimens or both per patient.

These samples are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are available for approved researchers

B NEO 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Tissue	DNA	Serum	Total Sample Numbers	Total Patient Numbers
ALL5 TOTAL	ALL5	141	3	29	6	0	0	70	249	3
CLL2 TOTAL	CLL2	0	0	5	0	0	0	0	5	2
CLL5 TOTAL	CLL5	325	0	165	238	0	0	93	821	21
CLL8 TOTAL	CLL8	68	0	42	179*	0	0	37	326	40
CLL11 TOTAL	CLL11	12	0	11	14	0	0	2	39	2
LY03 TOTAL	LY03	5	0	0	0	0	0	8	13	1
LY05 TOTAL	LY05	8	0	0	2	0	0	0	10	1
NHL11 TOTAL	NHL11	0	0	0	0	3	0	0	3	2
NHL14 TOTAL	NHL14	144	0	0	37	1	0	30	212	24
NHL16 TOTAL	NHL16	42	0	0	10	7	0	28	87	13
NHL21 TOTAL	NHL21	92	0	3	97	0	0	49	241	9
NHL24 TOTAL	NHL24	8	0	0	14	0	0	0	22	5
* = Mixtures of Carnoys and cell pellets - for further breakdown please contact Tissue Bank										
GRAND TOTAL (B NEO Trial and Non Trial)		6754	83	1378	3358	149	28	3567	15496	798

CMPD 'Trial' and 'Non Trial' Breakdown

Sample numbers include both diagnostic and follow up time points. Samples no's are from BM, PB or both per patient

CMPD 'Non Trial' Classification Breakdown	WHO 3rd Edition - CMPD Diseases	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Chronic Idiopathic Myelofibrosis and myelofibrosis with extramedullary haem	CMPD	CIM	52	0	11	29	33	125	7
Chronic Myeloproliferative Disease - Unclassifiable	CMPD	CMDU	59	0	22	24	19	124	4
Chronic Myeloid Leukaemia (incl. Chronic Phase and Blast Phase)	CMPD	CML	991	10	487	722	339	2549	44 **
Chronic Neutrophilic Leukaemia	CMPD	CNL	8	0	10	4	4	26	1
Essential Thrombocythemia	CMPD	ET	242	0	31	75	85	433	35
Polycythaemia Vera	CMPD	PV	138	0	35	29	42	244	20
Transformed Myelofibrosis - From PV	CMPD	TMPV	24	0	1	8	13	46	3
Transformed Myelofibrosis - From ET	CMPD	TMET	20	0	2		12	34	4
Chronic Eosinophilic Leukaemia/ Hypereosinophilic syndrome	CMPD	CEL/HES	8	0	0	9	4	21	1
TOTAL			1542	10	599	900	551	3602	119

** Also see "MDS/MPD and 'MPN' breakdown slides for additional myeloproliferative disease pts and samples e.g. other CMLs

CMPD 'Trial' and 'Non Trial' Breakdown

These samples below are from tissue bank consented trial patients. Excess samples above MRD requirements were processed & stored and are now available for approved researchers

CMPD 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
CML6 TOTAL	CML6	233	19	403	98	69	822	67
CML8 TOTAL	CML8	83	0	0	49	47	179	2
CML9 TOTAL	CML9	261	0	133	186	102	682	11
GRAND TOTAL (Trial and Non Trial)		2119	29	1135	1233	769	5285	199

HD 'Trial' and 'Non Trial' Breakdown

HD 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet		Serum	Total Sample Numbers	Total Patient Numbers
? Classification	?Classification	7	0	1	0	0	2	10	1
Nodular Sclerosis Classical Hodgkin Lymphoma	NSCHL	64	25	4	45	0	16	154	14
Mixed Cellularity Classical Hodgkins Lymphoma	MCCHL	51	9	0	35	0	14	109	4
Lymphocyte Rich Classical Hodgkins Lymphoma	LRCHL	0	0	0	0	0	0	0	0
Lymphocyte Depleted Classical Hodgkins Lymphoma	LDCHL	0	5	0	0	0	0	5	2
Nodular Lymphocyte Predominant Hodgkins Lymphoma	NLPHL	0	5	0	0	0	0	5	3
TOTAL		122	44	5	80	0	32	283	24

HD 'Trial' Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Plasma	Serum	Total Sample Numbers	Total Patient Numbers
HD3	HD3	0	0	0	0	193	0	193	89
HD8	HD8	32	1	0	40	0	39	112	7
TOTAL		32	1	0	40	193	39	305	96

GRAND TOTAL (Trial and Non Trial)		154	45	5	120	193	71	588	120
--	--	------------	-----------	----------	------------	------------	-----------	------------	------------

MDS 'Non Trial' and 'Trial' Breakdown

Sample numbers include both diagnostic and follow up time points.

Samples numbers are from BM, PB or both per patient

MDS 'Non Trial'	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Tissue	Serum	Total Sample Numbers	Total Patient Numbers
Classification Breakdown	?Classification									
No classification recorded		20	0	0	11	0	0	12	43	3
Acute Myeloid Leukemia with multilineage dysplasia with prior myelodysplasia	AMLAMDS	26	0	0	0	0	0	16	42	1
Myelodysplastic Syndrom associated with isolated (del) 5q chromosome abnormality	MDP5q	29	0	1	5	1	0	18	54	4
Myelodysplastic Syndrome - Unclassifiable	MDSU	34	0	0	10	1	0	36	81	8
Refractory Anaemia	RA	7	0	0	5	1	0	2	15	1
Refractory Anaemia with Excess Blasts	RAEB	28	4	2	4	2	0	22	62	6
RAEB-1	RAEB1	87	0	7	16	2	0	46	158	15
RAEB-2	RAEB2	178	6	35	72	7	0	135	433	20
Refractory Anaemia with Ringed Sideroblasts	RARS	10	0	9	2	1	0	9	31	2
Refractory cytopenia with multilineage dysplasia	RCMD	201	0	7	67	5	2	147	429	43
Refractory cytopenia with unilineage dysplasia	NW-RCUD	7	0	0	8	0	0	2	17	2
TOTAL		627	10	61	200	20	2	445	1365	105
MDS 'Trial' Breakdown	Tissue Bank Code	Trizol	RNA	Cryo	Cell Pellet	DNA	Tissue	Serum	Total Sample Numbers	Total Patient Numbers
MDS3										
TOTAL		254	0	29	103	0	0	120	506	18
MDS4										
TOTAL		72	0	27	110	0	0	3	212	24
GRAND TOTAL (Trial and Non Trial)		953	10	117	413	20	2	568	2083	147

T cell and NK cell Neoplasms 'Non Trial'

Classification Breakdown

Sample numbers include both diagnostic and follow up time points.
 Samples numbers are from BM, PB or both per patient

T/NK 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	RNA	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
No classification recorded	NO CLASS	13	0	0	0	6	8	27	2
Angioimmunoblastic T cell Lymphoma	AITCL	99	0	7	7	73	51	237	7
Anaplastic Large Cell Lymphoma	ALCL	89	1	4	0	66	44	204	5
Hepatosplenic T-cell Lymphoma	HSTCL	8	0	2	2	2	8	22	2
Mycosis Fungoides	MF	0	0	1	0	0	0	1	1
Extranodal NK/T cell Lymphoma Nasal Type	NKTCL	17	0	0	0	7	9	33	2
Peripheral T-Cell Lymphoma Unspecified	PTCLU	29	0	1	0	13	16	59	2
Sezary Syndrome	SS	34	0	0	0	28	7	69	2
Adult T-cell leukaemia/lymphoma	ATLL	37	0	0	10	17	14	78	3
Precursor T Lymphoblastic Leukemia/Lymphoma	TALL	334	17	0	106	153	180	790	10
T cell Large granular Lymphocytic Leukaemia	TLGL	34	0	0	2	10	20	66	8
T-cell Prolymphocytic Leukaemia	TPLL	75	0	0	41	60	11	187	2
TOTAL		769	18	15	168	435	368	1773	46

MDS/MPD and IDALP 'Non Trial' Classification Breakdown

MDS/MPD 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
No classification recorded	?Classification	15	0	9	6	8	38	2
Atypical Chronic Myeloid leukaemia, BCR-ABL1 negative	ACML	11	0	9	9	3	32	1
Chronic Myelomonocytic Leukaemia	CMML	486	0	171	350	137	1144	36
Myelodysplastic/Myeloproliferative - unclassifiable	MDS/MPDU	98	0	25	101	28	252	10
TOTAL		610	0	214	466	176	1466	49

IDALP 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Methotrexate-associated lymphoproliferative Disorders	MTALPD	5	0	0	2	5	12	1
New Who	NWLDPID	6	0	0	5	6	17	1
Post transplant Lymphoproliferative Disorders	PTLD	48	4	0	42	7	101	2
New Who	NWOILD	4	0	0	4	3	11	1
TOTAL		63	4	0	53	21	141	5

MISC, HIST and MAST

'Non Trial' Patient Classification Breakdown

MISCELLANEOUS 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
As yet unable to classify into major diagnostic group	MISC	107	3	6	48	80	244	19
TOTAL		107	3	6	48	80	244	19

HISTIOCYTIC and DENDRITIC Cell NEOPLASMS (HIST) 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
NO Patients or Samples available for this diagnosis		0	0	0	0	0	0	0
TOTAL		0	0	0	0	0	0	0

MAST 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Systemic mastocytosis with associated clonal , haematological non mast cell lineage disease	SMS	7	0	0	4	9	20	1
TOTAL		7	0	0	4	9	20	1

Myeloproliferative Neoplasms (MPN) and Myeloid and Lymphoid Neoplasms (MALN)

'Non Trial' Patient Classification Breakdown

MPN 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
Chronic Idiopathic Myelofibrosis	CIM	18	0	2	16	7	43	4
Chronic Myelogenous Leukaemia BRC-ABL1 positive (incl. Chronic Phase and Blast Phase)	CML	328	0	227	345	28	928	15**
Essential Thrombocythemia	ET	33	0	0	31	11	75	6
Systemic Mastocytosis	NW-SM	12	0	0	10	4	26	2
Myeloproliferative Neoplasm Unclassifiable	NW - MPNU	16	0	1	13	7	37	4
Polycythaemia Vera	PV	1	0	0	0	0	1	1
		408	0	230	415	57	1110	32

** Also see 'CMPD' breakdown slide for additional myeloproliferative disease pts and samples e.g. Other CML's

MALN 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
New Who - Myeloid and lymphoid neoplasms with <i>FGFR1</i> abnormalities	NW-FGFR1	13	44	11	7	7	82	1
TOTAL		13	44	11	7	7	82	1

Precursor Lymphoid Neoplasms (PLN)

'Non Trial' Patient Classification Breakdowns

PLN 'Non Trial' Classification Breakdown	Tissue Bank Code	Trizol	Tissue	Cryo	Cell Pellet	Serum	Total Sample Numbers	Total Patient Numbers
? Classification	NO CLASS	6	0	6	1	0	13	1
Precursor B Lymphoblastic Leukaemia	PBALL	36	0	0	52	10	98	2
B Lymphoblastic Leukaemia/Lymphoma with t(12;21); TEL-AML1	NW - BLL1221	5	0	1	2	0	8	1
New Who - B Lymphoblastic leukaemia/lymphoma with t(9;22)	NW-BLL922	38	0	26	49	10	123	2
New Who - B Lymphoblastic leukaemia/ lymphoma not otherwise specified	NW-BLLNOS	50	0	7	38	14	109	4
New Who - B Lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged	NW-BLLMLL	44	0	48	42	6	140	1
New who - T Lymphoblastic leukaemia/lymphoma	NW-TLL	23	0	2	0	15	40	1
TOTAL		202	0	90	184	55	531	12